

Cristina Lamas Oliveira

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9394593/publications.pdf>

Version: 2024-02-01

45
papers

741
citations

687363

13
h-index

552781

26
g-index

48
all docs

48
docs citations

48
times ranked

985
citing authors

#	ARTICLE	IF	CITATIONS
1	Hospital capacity and admission rate may be a factor of importance to mortality in COVID-19. <i>Infectious Diseases</i> , 2022, 54, 238-240.	2.8	5
2	Implications of Heterogeneity of Epithelial-Mesenchymal States in Acromegaly Therapeutic Pharmacologic Response. <i>Biomedicines</i> , 2022, 10, 460.	3.2	7
3	Integrative clinical, radiological and molecular analysis for predicting remission and recurrence of Cushing's disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, , .	3.6	3
4	Data mining analyses for precision medicine in acromegaly: a proof of concept. <i>Scientific Reports</i> , 2022, 12, .	3.3	11
5	Molecular determinants of enhanced response to somatostatin receptor ligands after debulking in large GH-producing adenomas. <i>Clinical Endocrinology</i> , 2021, 94, 811-819.	2.4	9
6	ENSAT registry-based randomized clinical trials for adrenocortical carcinoma. <i>European Journal of Endocrinology</i> , 2021, 184, R51-R59.	3.7	11
7	Pasireotide in the Personalized Treatment of Acromegaly. <i>Frontiers in Endocrinology</i> , 2021, 12, 648411.	3.5	19
8	Reconocer el trabajo de los revisores para mejorar las publicaciones científicas. <i>Endocrinología, Diabetes Y Nutrición</i> , 2021, 68, 293-295.	0.3	0
9	Surgical outcomes in the pheochromocytoma surgery. Results from the PHEO-RISK STUDY. <i>Endocrine</i> , 2021, 74, 676-684.	2.3	18
10	Risk factors for intraoperative complications in pheochromocytomas. <i>Endocrine-Related Cancer</i> , 2021, 28, 695-703.	3.1	17
11	Cerebral hemodynamics in obesity: relationship with sex, age, and adipokines in a cohort-based study. <i>GeroScience</i> , 2021, 43, 1465-1479.	4.6	4
12	CD133 Expression in Medullary Thyroid Cancer Cells Identifies Patients with Poor Prognosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 3548-3561.	3.6	5
13	Differential Expression of MicroRNAs in Silent and Functioning Corticotroph Tumors. <i>Journal of Clinical Medicine</i> , 2020, 9, 1838.	2.4	5
14	Increased E2F1 mRNA and miR-17-5p Expression Is Correlated to Invasiveness and Proliferation of Pituitary Neuroendocrine Tumours. <i>Diagnostics</i> , 2020, 10, 227.	2.6	10
15	Guía práctica sobre la evaluación inicial, seguimiento y tratamiento de los incidentalomas adrenales. Grupo de patología adrenal de la Sociedad Española de Endocrinología y Nutrición. <i>Endocrinología, Diabetes Y Nutrición</i> , 2020, 67, 408-419.	0.3	32
16	Oseltamivir-induced toxic epidermal necrolysis in a patient with Cushing's disease. <i>Indian Journal of Dermatology, Venereology and Leprology</i> , 2020, 86, 515.	0.6	4
17	Integrative multi-omics analysis identifies a prognostic miRNA signature and a targetable miR-21-3p/TSC2/mTOR axis in metastatic pheochromocytoma/paraganglioma. <i>Theranostics</i> , 2019, 9, 4946-4958.	10.0	54
18	DNA Methylation of Tumor Suppressor Genes in Pituitary Neuroendocrine Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 1272-1282.	3.6	21

#	ARTICLE	IF	CITATIONS
19	How Valuable Is the RT-qPCR of Pituitary-Specific Transcription Factors for Identifying Pituitary Neuroendocrine Tumor Subtypes According to the New WHO 2017 Criteria?. <i>Cancers</i> , 2019, 11, 1990.	3.7	12
20	CT Characteristics of Pheochromocytoma: Relevance for the Evaluation of Adrenal Incidentaloma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 312-318.	3.6	96
21	MEN1-associated primary hyperparathyroidism in the Spanish Registry: clinical characteristics and surgical outcomes. <i>Endocrine Connections</i> , 2019, 8, 1416-1424.	1.9	14
22	Silent somatotropinomas. <i>Minerva Endocrinologica</i> , 2019, 44, 137-142.	1.8	7
23	Estudio de mutaciones germinales en pacientes con feocromocitomas y paragangliomas atendidos en un hospital universitario de tercer nivel: ¿quÃ© pacientes se estudian y quÃ© resultados se encuentran?. <i>Endocrinología, Diabetes Y Nutrición</i> , 2018, 65, 508-514.	0.3	2
24	Is it time to consider the expression of specific-pituitary hormone genes when typifying pituitary tumours?. <i>PLoS ONE</i> , 2018, 13, e0198877.	2.5	13
25	PheoSeq. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 575-588.	2.8	63
26	Contribution of molecular analysis to the typification of the non-functioning pituitary adenomas. <i>PLoS ONE</i> , 2017, 12, e0180039.	2.5	18
27	Long-lasting response to oral therapy in a young male with monogenic diabetes as part of HNF1B-related disease. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2017, 2017, .	0.5	12
28	Ovarian insular carcinoid tumor responsible for carcinoid heart disease. <i>Medicina Clínica (English)</i> Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.2	0
29	RET Cys634Arg mutation confers a more aggressive multiple endocrine neoplasia type 2A phenotype than Cys634Tyr mutation. <i>European Journal of Endocrinology</i> , 2015, 172, 301-307.	3.7	32
30	GuÃa clÃnica de manejo de la diabetes insÃpida y del sÃndrome de secreciÃn inapropiada de hormona antidiurÃtica en el postoperatorio de la cirugÃa hipofisaria. <i>Endocrinología Y Nutricion: Organo De La Sociedad Espanola De Endocrinología Y Nutricion</i> , 2014, 61, e15-e24.	0.8	36
31	Metabolic consequences of craniopharyngioma and their management. <i>Endocrinología Y Nutrición (English Edition)</i> , 2013, 60, 529-534.	0.5	1
32	Consecuencias metabÃ³licas del craneofaringioma y su tratamiento. <i>Endocrinología Y Nutricion: Organo De La Sociedad Espanola De Endocrinología Y Nutricion</i> , 2013, 60, 529-534.	0.8	3
33	Importance of clinical variables in the diagnosis of MODY2 and MODY3. <i>Endocrinología Y Nutricion: Organo De La Sociedad Espanola De Endocrinología Y Nutricion</i> , 2011, 58, 341-346.	0.8	4
34	Clinical differences between patients with MODY-3, MODY-2 and type 2 diabetes mellitus with I27L polymorphism in the HNF1Î± gene. <i>Endocrinología Y Nutricion: Organo De La Sociedad Espanola De Endocrinología Y Nutricion</i> , 2010, 57, 4-8.	0.8	8
35	Rhabdomyolysis due to primary hyperaldosteronism. <i>Endocrinología Y Nutricion: Organo De La Sociedad Espanola De Endocrinología Y Nutricion</i> , 2009, 56, 431-434.	0.8	12
36	MetodologÃa diagnÃstica en la identificaciÃn del Cushing ectÃ³pico. <i>Endocrinología Y Nutricion: Organo De La Sociedad Espanola De Endocrinología Y Nutricion</i> , 2007, 54, 432-437.	0.8	4

#	ARTICLE	IF	CITATIONS
37	Malignant prolactinoma with multiple bone and pulmonary metastases. <i>Journal of Neurosurgery: Pediatrics</i> , 2004, 101, 116-121.	1.3	8
38	Is unilateral adrenalectomy an alternative treatment for ACTH-independent macronodular adrenal hyperplasia?: Long-term follow-up of four cases. <i>European Journal of Endocrinology</i> , 2002, 146, 237-240.	3.7	57
39	The Complete Normalization of the Adrenocortical Function as the Criterion of Cure after Transsphenoidal Surgery for Cushing's Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 5695-5699.	3.6	92
40	Diabetic ketoacidosis simulator: a new learning tool for a life threatening condition. <i>Endocrine Abstracts</i> , 0, , .	0.0	0
41	Clinical and biochemical outcomes in surgically treated patients with primary aldosteronism. A multicentric retrospective study. <i>Endocrine Abstracts</i> , 0, , .	0.0	0
42	Adrenal schwannoma presenting as an adrenal incidentaloma in a pregnant woman. <i>Endocrine Abstracts</i> , 0, , .	0.0	0
43	Why don't corticotroph tumours always produce Cushing disease?. <i>Endocrine Abstracts</i> , 0, , .	0.0	0
44	Hypermethylation of tumour suppressor genes in pituitary adenomas: contribution to oncogenesis and tumour behaviour. <i>Endocrine Abstracts</i> , 0, , .	0.0	0
45	Preliminary study of POU1F1 (Pit1) gene expression in lactotroph and thyrotroph neuroendocrine tumours. <i>Endocrine Abstracts</i> , 0, , .	0.0	0